Difficulty: Medium
Average Score: 76%
Practice
Which preparation of Vitamin K should not be injected in the new born?
Correct answer
D
Rationale
In the context of administering Vitamin K to newborns, it is crucial to understand the differences between the various preparations available. In this question, the correct answer is D) Both (b) and (c) - Menadione and Menadione sodium diphosphate.
Menadione and its derivative Menadione sodium diphosphate should not be injected in newborns due to their potential toxicity and adverse effects, particularly in the hemolytic and jaundice-inducing effects on infants. Menadione has been associated with hemolytic anemia, hyperbilirubinemia, and kernicterus in newborns. Therefore, it is contraindicated for use in newborns.
On the other hand, option A) Phytonadione is the preferred form of Vitamin K for newborn administration. Phytonadione is a more stable and safer form of Vitamin K that does not pose the same risks as Menadione and its derivative. It is effective in preventing hemorrhagic disease of the newborn without the associated toxicity.
Educationally, this question highlights the importance of understanding the specific preparations and their suitability for different patient populations. It emphasizes the critical nature of medication administration in newborns and the potential risks associated with using certain formulations. Healthcare providers need to be aware of these distinctions to ensure the safety and well-being of their patients, especially vulnerable populations like newborns.
Menadione and its derivative Menadione sodium diphosphate should not be injected in newborns due to their potential toxicity and adverse effects, particularly in the hemolytic and jaundice-inducing effects on infants. Menadione has been associated with hemolytic anemia, hyperbilirubinemia, and kernicterus in newborns. Therefore, it is contraindicated for use in newborns.
On the other hand, option A) Phytonadione is the preferred form of Vitamin K for newborn administration. Phytonadione is a more stable and safer form of Vitamin K that does not pose the same risks as Menadione and its derivative. It is effective in preventing hemorrhagic disease of the newborn without the associated toxicity.
Educationally, this question highlights the importance of understanding the specific preparations and their suitability for different patient populations. It emphasizes the critical nature of medication administration in newborns and the potential risks associated with using certain formulations. Healthcare providers need to be aware of these distinctions to ensure the safety and well-being of their patients, especially vulnerable populations like newborns.